Special Issue "Photodynamic Therapy (PDT) in Oncology"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 31 October 2019

Special Issue Editors

Guest Editor
Prof. Dr. Ángeles Juarranz

Department of Biology, Faculty of Sciences, Universidad Autónoma de Madrid, 28049 Madrid, Spain
Phone: 34-914978247
Guest Editor
Dr. Yolanda Gilaberte

Department of Dermatology, University Hospital Miguel Servet, IIS Aragón, 50009 Zaragoza, Spain
Guest Editor
Dr. Salvador González

Department of Medicine and Medical Specialties, Alcalá de Henares University, 28805 Madrid, Spain

Special Issue Information

Dear Colleagues,

Photodynamic therapy (PDT) is a minimally invasive therapeutic modality approved for treatment of several types of cancer and non-oncological disorders. PDT is able to selectively destroy tumours accessible to light, being used in dermatology for the treatment of non-melanoma skin cancers (basal cell carcinoma and Bowen disease) and precancerous lesions (actinic keratosis) as well as for the treatment of head and neck cancer, endoscopically accessible tumours such as pulmonary, bladder, gastrointestinal and gynaecological neoplasms. Moreover, interstitial PDT has been proposed for solid tumors such as brain and prostate cancer. Additionally, PDT can be used for cancer diagnose being theragnosis a promising technique based for targeted fluorescent imaging and PDT. Although photofrin, aminolevulinic acid and its ester derivatives are the main compounds used in clinical trials, newer photosensitizers and delivery tools are being evaluated. From the first articles published by the group of Dougherty, T.J. that describe the advantages and applications of PDT in the eighties, many investigations the mechanisms of action, new photosensitizers and new cancer applications have been performed.

This special Issue on Cancers is focused on photodynamic therapy and it would include original articles on aspects related with treatment of cancer. In particular, research on photochemical mechanisms, new photosensitizers and delivery tools, cellular and tissue targets, cellular response (cell death and survival), vascular damage and immune response by using different cellular and animal models. Translational work describing the value of PDT alone or in combination with other treatment modalities in cancer treatment will also be included.

Prof. Dr. Ángeles Juarranz
Dr. Yolanda Gilaberte
Dr. Salvador González
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • photodynamic therapy
  • photosensitizers
  • action mechanisms
  • in vitro and in vivo models
  • applications in cancer
  • delivery tools
  • resistance mechanisms

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:


Open AccessArticle Efficacy of 5-Aminolevulinic Acid in Photodynamic Detection and Photodynamic Therapy in Veterinary Medicine
Cancers 2019, 11(4), 495; https://doi.org/10.3390/cancers11040495
Received: 20 March 2019 / Revised: 3 April 2019 / Accepted: 5 April 2019 / Published: 7 April 2019
PDF Full-text (4499 KB) | HTML Full-text | XML Full-text
5-Aminolevulinic acid (5-ALA), a commonly used photosensitizer in photodynamic detection (PDD) and therapy (PDT), is converted in situ to the established photosensitizer protoporphyrin IX (PpIX) via the heme biosynthetic pathway. To extend 5-ALA-PDT application, we evaluated the PpIX fluorescence induced by exogenous 5-ALA [...] Read more.
5-Aminolevulinic acid (5-ALA), a commonly used photosensitizer in photodynamic detection (PDD) and therapy (PDT), is converted in situ to the established photosensitizer protoporphyrin IX (PpIX) via the heme biosynthetic pathway. To extend 5-ALA-PDT application, we evaluated the PpIX fluorescence induced by exogenous 5-ALA in various veterinary tumors and treated canine and feline tumors. 5-ALA-PDD sensitivity and specificity in the whole sample group for dogs and cats combined were 89.5 and 50%, respectively. Notably, some small tumors disappeared upon 5-ALA-PDT. Although single PDT application was not curative, repeated PDT+/−chemotherapy achieved long-term tumor control. We analyzed the relationship between intracellular PpIX concentration and 5-ALA-PDT in vitro cytotoxicity using various primary tumor cells and determined the correlation between intracellular PpIX concentration and 5-ALA transporter and metabolic enzyme mRNA expression levels. 5-ALA-PDT cytotoxicity in vitro correlated with intracellular PpIX concentration in carcinomas. Ferrochelatase mRNA expression levels strongly negatively correlated with PpIX accumulation, representing the first report of a correlation between mRNA expression related to PpIX accumulation and PpIX concentration in canine tumor cells. Our findings suggested that the results of 5-ALA-PDD might be predictive for 5-ALA-PDT therapeutic effects for carcinomas, with 5-ALA-PDT plus chemotherapy potentially increasing the probability of tumor control in veterinary medicine. Full article
(This article belongs to the Special Issue Photodynamic Therapy (PDT) in Oncology)

Figure 1

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top